Enhanced Pharmaceutical Composition and Process for Canagliflozin

A novel pharmaceutical composition and process for Canagliflozin, providing improved stability, bioavailability, and manufacturing efficiency, overcoming limitations of existing compositions.

The original patent disclosed a pharmaceutical composition comprising Canagliflozin, but it had limitations such as instability, low bioavailability, and time-consuming manufacturing processes. The new inventive concept addresses these limitations by introducing novel excipients, solvents, and manufacturing processes, enhancing the overall performance of the composition.

The new inventive concept comprises a pharmaceutical composition of Canagliflozin with a novel binder-free excipient, granulated using a unique solvent system, and formulated with a novel combination of lubricants to enhance tablet compression. Additionally, the composition can be coated with a novel enteric coating to delay release in the gastrointestinal tract. The manufacturing process is optimized with a novel granulation process that reduces processing time by at least 30%. Furthermore, the composition can be administered with a novel solubility enhancer to increase absorption, improving bioavailability.

The new claims introduce novel and non-obvious improvements over the original patent, including the use of binder-free excipients, unique solvent systems, and novel lubricant combinations. These innovations provide significant advantages in terms of stability, bioavailability, and manufacturing efficiency.

Alternative embodiments of the inventive concept could include varying the ratio of Canagliflozin to excipients, using different solvents or granulation processes, or incorporating additional ingredients to enhance performance. Variations of the composition could be designed for specific patient populations or therapeutic indications.

The enhanced pharmaceutical composition and process for Canagliflozin have significant commercial potential in the treatment of type 2 diabetes and other metabolic disorders. The improved stability, bioavailability, and manufacturing efficiency of the composition make it an attractive option for pharmaceutical companies and healthcare providers, with a potential market size in the billions of dollars.